International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund’s assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of ...
25 Southampton Buildings
London, WC2A 1AL
Founded in 1994
David Clough to Retire as Non-Executive Director of International Biotechnology Trust plc
Dec 9 15
International Biotechnology Trust plc announced that Dr. David Clough will retire as a non-executive Director of the company, with effect from 9 December 2015.
International Biotechnology Trust plc, Annual General Meeting, Dec 09, 2015
Nov 27 15
International Biotechnology Trust plc, Annual General Meeting, Dec 09, 2015., at 12:30 GMT Standard Time. Location: BNP Paribas Fortis. Agenda: To receive the directors' report and the audited financial statements for the year ended 31 August 2015; to approve the annual report on directors' remuneration for the year ended 31 August 2015; to re-elect Alan Clifton and Véronique Bouchet as director of the company; to elect Mrs. Caroline Gulliver as a director of the company; to re-appoint PricewaterhouseCoopers LLP as the Independent Auditors; to consider the company continue as an investment trust for a further two year; to authorise to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the company; to consider the board be given power to allot equity securities; and to consider General Meeting (other than an AGM) may be called on not less than 14 clear days' notice.
International Biotechnology Trust plc Announces Audited Group Earnings Results for the Year Ended August 31, 2015
Nov 5 15
International Biotechnology Trust plc announced audited group earnings results for the year ended August 31, 2015. For the year, the company reported profit before finance costs and tax of £78,699,000 compared to £44,863,000 a year ago. Profit on ordinary activities before tax was £78,533,000 compared to £44,754,000 a year ago. Profit for the year attributable to owners of the parent company was £78,479,000 or 178.54 pence per basic and diluted share compared to £44,719,000 or 81.30 pence per basic and diluted share a year ago. Net cash flows generated from operating activities were £38,897,000 compared to net cash flows used in operating activities of £2,231,000 a year ago.